Hematology Flashcards
Explain the adhesion part of platelets:
Following vessel injury, vWF binds to exposed collagen, and plts use the GP 1b to ADHERE to the damaged endothelium via vWF-GP Ib interaction.
Explain the activation process:
Plt adhesion results in ACTIVATION, where GIIb/IIIa receptors are exposed and release of granules occur. Granules release thromboxane A2 and platelet activating factor which lead to aggregation and vasoconstriction.
Final step of platelet formation:
The final step of the platelet plug involves the formation of thrombin by soluble coagulation factors and the plts AGGREGATE with each other by binding a crosslink, glue-like pattern of fibrinogen with the GP IIb/IIIa receptors.
Vitamin k dependent clotting factors:
Factors: 2, 7, 9, 10; Proteins C, S
Intrinsic pathway:
12 → 11 → 9 → 8 →10 →5 → 2 → 1. Answer A is the intrinsic pathway, which was thought of as initiation of the clot within the intravascular space. Answer B is the extrinsic pathway, which means that the clot formation is initiated outside the intravascular space.
Does intrinsic or extrinsic start first? And if so-how?
In nearly, if not always, all cases, the coagulation pathway is initiated by the extrinsic pathway; that is endothelial damage results in release of tissue factor (3). The intrinsic pathway amplifies this only after the extrinsic pathway has been initiated.
What is plasminogen? Where is it made and where can it be found? When is it incorporated? What activates it? And what does it do once activated?
Plasminogen is an inactive protein made by the liver and is found in the plasma. With endothelial damage, a platelet plug and fibrin formation occurs, as discussed in the above few questions. During the normal crosslinking of fibrin, plasminogen is incorporated, like tiny little time bombs ready to degrade fibrin once activated. With endothelial damage, not only does vWF bind to exposed collagen and tissue factor (Factor 3) released from the endothelial cells, but tPA is also released. tPA activates the plasminogen into plasmin which degrades cross-linked fibrin, releasing D-dimers (ignites the bombs). Plasmin activation COUNTERACTS the clotting cascade keeping it in check
What inhibits actions of plasmin? What encourages it? (Drug wise)
But plasmin and tPA - you need to know and understand. Why? Aminocaproic acid (Amicar), Tranexamic acid, and Aprotinin inhibit the actions of plasmin and tPA promotes the action/ formation of plasmin.
PT tests the _____ pathway?
PTT?
ACT
Bleeding time?
pT: Extrinsic
PTT: intrinsic
ACT: intrinsic
Bleeding time: platelet function
Hemophilia A-deficiency in what? What percentage does a patient need to have for minor or major surgery?
Patients with haemophilia A have a factor 8 deficiency, which is a hereditary X- chromosome linked coagulopathy. Patients need 50% activity for minor surgery and 100% for major surgery.
Hemophilia A treatment options: DDAVP, Cryo, factor 8, FFP?
Factor 8:c concentrate delivers 40 units per cc (meaning for an average patient with minimal activity they would only need 30-40 cc). Cryoprecipitate delivers 5-10 units per cc, making it the second best method. Typically a cryo bag will have about 100 units, leading to relatively large volumes needed. FFP has only 1 unit per cc, requiring at least 1.2 liters in a 70 kg patient to increase function to 50%. DDAVP works by up-regulating natural production of Factor 8 and von Willebrand (vWF), increasing present levels by 2-4 times. In this patient that would still be insufficient.
Type 1 vWD: how does it work, what can you do to treat it? Is type 1 a quantitative or qualitative thing?
vWD is a common cause of hereditary coagulopathies and can lead to excessive surgical bleeding when in the homozygous form. There are many types of vWD, but by far the most common is Type I. Type I vWD has a quantitative defect in the vWF, but is responsive to DDAVP. DDAVP causes increased release of vWF from the endothelium, and is the preferred treatment for vWD in most instances.
Tell me about type 2 and type 3 Von willebeand disease. What can you do to treat it?
Type IIB vWD, DDAVP can lead to paradoxical thrombosis and platelet consumption, and with Type III DDAVP is ineffective.
I’m pts with VWF type 1, how can you treat it? Can you give Neuraxial, If so-what should you do?
For major surgery DDAVP alone is insufficient and Humate-P (factor 8/ vWF concentrate), cryoprecipitate, or FFP should be given. Far smaller volumes of cryoprecipitate and Humate-P are needed to raise factor 8 and vWF levels than FFP, and are therefore preferred treatments. vWD does not routinely rise PTT, but does increase bleeding time. There are no specific recommendations to withhold neuroaxial anesthetic techniques from patients with vWD (answer “Humate-P needs to be administered 30 minutes prior to epidural placement”), although many practitioners that would be willing to place an epidural or spinal in a patient with vWD would use DDAVP prior to epidural placement.
DIC-how does it happen? What do the labs look like? Treatment? What causes increased D dimer? What are some causes?
DIC is a process of uncontrolled fibrin production with platelet and factor consumption. In the setting of sepsis, immune complexes, endotoxin, and cytokines cause the activation of various parts of the clotting cascade leading to wide-spread fibrin formation and thrombosis. Eventually as factors and platelets are consumed in forming the thromboses, there is a factor deficiency and thrombocytopaenia, leading to coagulopathy.
The process of widespread thrombosis also leads to increased fibrin breakdown by plasmin, leading to increased D-Dimers. Classically on labs one sees a low platelet count (must be present to fit definition of DIC), increased PT & PTT (consumption of factors), decreased fibrinogen and increased D-Dimers (fibrinolysis). Other common boards causes of DIC include retained placenta, fetal demise, burns, trauma, transfusion reactions, cancer, malignant hyperthermia, and embolism (especially amniotic). These result in increased tissue factor (TF) release and initiation of the extrinsic pathway.
Treatment: primary treatment is treating the underlying cause of DIC, but you can also give platelets, FFP, and cryo 😃
IgG antibodies towards Plt antigens leads to Plt destruction and easy bleeding describes: __. How can the antibodies be removed? For major surgery, what should the platelets be? How much of an increase does one pack of platelets make?
ITP.
IgG antibodies can be removed by plasmapharesis or combated with IVIG therapy, steroids, and various immunosupressants
For major surgery, such as a splenectomy, the Plt count should be 100,000.
One unit of plasmapharesis Plts is the equivalent of a 6-pack. Therefore 6 X 5,000- 10,000 = 30,000 - 60,000 increase in Plt count
ABO and Rh and their reactions with FFP and PRBC
This is a surprisingly misunderstood, but simple concept. Plasma from patients can contain anti-ABO and anti-Rh antibodies. Therefore a donor who is B, Rh – may have formed antibodies towards both the A antigen and the Rh antigen. Likewise, a patient who is AB, Rh + will not have antibodies against AB or Rh. Therefore, just as the O, Rh – patient is the universal pRBC donor, the AB, Rh+ patient is the universal FFP donor. That being said, even when wrong typed FFPs are given, it is rare to have a serious transfusion reaction.
Cryo is a poor source of what?
Cryoprecipitate is a poor source of vitamin k dependent factors, including factor 9 which is responsible for Haemophilia B. Most common reasons to transfuse cryoprecipitate is low fibrinogen, vWF, or factor 8 (Haemophilia A).
A patient presents with cerebral haemorrhage while on plavix and warfarin. What would you give?
Platelets for Plavix and recombinant factors 7 or 9 (PCC), which have 2,7,9,10 if 4 factor and no 7 if 3 factor
When would you wash, irradiate, or leukoresuce blood cells?
Washing red blood cells (RBCs) is used, among other things, to remove IgA so that anaphylactic reactions don’t occur in IgA deficient patients. Leukocytes are responsible for febrile reactions and alloimmunization; therefore, the reduction of these cells reduces the risk of the complication. Irradiation, which destroys DNA, is used to prevent graft vs host disease. Recall that erythrocytes do not have DNA.